Search results
Results from the WOW.Com Content Network
The aims of EULAR are to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with musculoskeletal diseases by the ...
Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.. Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system" [6] via a process called trogocytosis. [3]
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. [1] It targets interferon a. [2] Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials. [3] [4] [5]
Lupus, formally called systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. [1] Symptoms vary among people and may be mild to severe. [ 1 ]
Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE) and childhood-onset systemic lupus erythematosus which is a more severe form of SLE that develops in children up to 18 years old; both are autoimmune diseases. [3] [4] It is a type of glomerulonephritis in which the glomeruli become inflamed.
The main indication for testing for lupus anticoagulant is a suspected antiphospholipid syndrome, whose main manifestations are blood clots in both arteries and veins as well as pregnancy-related complications such as miscarriage, stillbirth, preterm delivery, and severe preeclampsia.
Neonatal lupus erythematosus is an autoimmune disease in an infant born to a mother with anti-Ro/SSA and with or without anti-La/SSB antibodies. [1] [2] The disease most commonly presents with a diffuse/periorbital rash resembling subacute cutaneous lupus erythematosus and can have systemic abnormalities such as complete heart block or hepatosplenomegaly. [3]
He completed his A-Levels in 1994 at Milambo Secondary School in Tabora Region having studied economics, geography and mathematics. From 1996 to 1999, he pursued his Advance Diploma in Economic Planning at the Institute of Development Studies at Mzumbe University; followed by an MBA in Corporate Management and graduating from the same alma mater in 2001.